Evolent Health, Inc. (EVH)
USD 10.69
(7.44%)
USD 10.69
(7.44%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 1.96 Billion USD | 45.26% |
| 2022 | 1.35 Billion USD | 48.91% |
| 2021 | 907.95 Million USD | -11.2% |
| 2020 | 1.02 Billion USD | 20.8% |
| 2019 | 846.38 Million USD | 34.98% |
| 2018 | 627.06 Million USD | 44.17% |
| 2017 | 434.95 Million USD | 71.11% |
| 2016 | 254.18 Million USD | 162.38% |
| 2015 | 96.87 Million USD | 0.0% |
| 2014 | - USD | -100.0% |
| 2013 | 25.67 Million USD | 207.58% |
| 2012 | 8.34 Million USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 647.14 Million USD | 1.17% |
| 2024 Q1 | 639.65 Million USD | 15.03% |
| 2023 Q2 | 469.13 Million USD | 9.69% |
| 2023 Q4 | 556.05 Million USD | 8.81% |
| 2023 FY | 1.96 Billion USD | 45.26% |
| 2023 Q3 | 511.01 Million USD | 8.93% |
| 2023 Q1 | 427.69 Million USD | 11.83% |
| 2022 FY | 1.35 Billion USD | 48.91% |
| 2022 Q2 | 319.93 Million USD | 7.7% |
| 2022 Q3 | 352.58 Million USD | 10.2% |
| 2022 Q1 | 297.05 Million USD | 19.61% |
| 2022 Q4 | 382.43 Million USD | 8.47% |
| 2021 Q3 | 222.47 Million USD | 0.19% |
| 2021 Q4 | 248.35 Million USD | 11.64% |
| 2021 Q1 | 215.07 Million USD | -20.91% |
| 2021 Q2 | 222.05 Million USD | 3.25% |
| 2021 FY | 907.95 Million USD | -11.2% |
| 2020 Q3 | 264.59 Million USD | 10.88% |
| 2020 Q2 | 238.63 Million USD | -3.5% |
| 2020 FY | 1.02 Billion USD | 20.8% |
| 2020 Q4 | 271.92 Million USD | 2.77% |
| 2020 Q1 | 247.28 Million USD | 4.55% |
| 2019 FY | 846.38 Million USD | 34.98% |
| 2019 Q1 | 197.75 Million USD | 2.41% |
| 2019 Q4 | 236.52 Million USD | 7.44% |
| 2019 Q3 | 220.14 Million USD | 14.68% |
| 2019 Q2 | 191.95 Million USD | -2.93% |
| 2018 FY | 627.06 Million USD | 44.17% |
| 2018 Q4 | 193.1 Million USD | 28.78% |
| 2018 Q2 | 144.29 Million USD | 3.28% |
| 2018 Q1 | 139.71 Million USD | 22.85% |
| 2018 Q3 | 149.94 Million USD | 3.91% |
| 2017 FY | 434.95 Million USD | 71.11% |
| 2017 Q4 | 113.72 Million USD | 5.39% |
| 2017 Q3 | 107.91 Million USD | 0.79% |
| 2017 Q2 | 107.07 Million USD | 0.78% |
| 2017 Q1 | 106.23 Million USD | 20.71% |
| 2016 Q1 | 49.44 Million USD | 7.36% |
| 2016 FY | 254.18 Million USD | 162.38% |
| 2016 Q4 | 88.01 Million USD | 46.17% |
| 2016 Q3 | 60.21 Million USD | 6.53% |
| 2016 Q2 | 56.51 Million USD | 14.3% |
| 2015 FY | 96.87 Million USD | 0.0% |
| 2015 Q2 | 10.41 Million USD | -71.89% |
| 2015 Q3 | 40.4 Million USD | 288.0% |
| 2015 Q4 | 46.05 Million USD | 13.99% |
| 2015 Q1 | 37.04 Million USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2014 Q2 | - USD | -100.0% |
| 2014 Q4 | - USD | 0.0% |
| 2014 Q1 | 20.07 Million USD | 1138.59% |
| 2014 FY | - USD | -100.0% |
| 2013 FY | 25.67 Million USD | 207.58% |
| 2013 Q4 | -1.93 Million USD | 0.0% |
| 2012 FY | 8.34 Million USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| American Well Corporation | 259.04 Million USD | -658.123% |
| Doximity, Inc. | 475.42 Million USD | -313.085% |
| MultiPlan Corporation | 961.52 Million USD | -104.248% |
| Phreesia, Inc. | 356.29 Million USD | -451.193% |
| Teladoc Health, Inc. | 2.6 Billion USD | 24.536% |
| Veeva Systems Inc. | 2.36 Billion USD | 16.913% |